Peptide aggregation in neurodegenerative disease.
暂无分享,去创建一个
[1] R. Wetzel,et al. Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[2] L. Tjernberg,et al. Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand (*) , 1996, The Journal of Biological Chemistry.
[3] G. Forloni,et al. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. , 1994, The Journal of biological chemistry.
[4] W. Surewicz,et al. Solution Structure of the E200K Variant of Human Prion Protein , 2000, The Journal of Biological Chemistry.
[5] H. Vinters,et al. Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. , 1999, Biochemistry.
[6] J Collinge,et al. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. , 1999, Science.
[7] S. Prusiner,et al. Rapid Acquisition of β-Sheet Structure in the Prion Protein Prior to Multimer Formation , 1998, Biological chemistry.
[8] L. Iversen,et al. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] R. Murphy,et al. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. , 2001, Biophysical journal.
[10] B. Solomon,et al. Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .
[11] B. Chesebro,et al. Species-Independent Inhibition of Abnormal Prion Protein (PrP) Formation by a Peptide Containing a Conserved PrP Sequence , 1999, Journal of Virology.
[12] P. Fraser,et al. pH-dependent structural transitions of Alzheimer amyloid peptides. , 1991, Biophysical journal.
[13] F. Cohen,et al. Scrapie infectivity is independent of amyloid staining properties of the N-terminally truncated prion protein. , 2000, Journal of Structural Biology.
[14] J R Ghilardi,et al. Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid. , 2000, Journal of structural biology.
[15] R. Kopito,et al. Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.
[16] B. Caughey. Transmissible spongiform encephalopathies, amyloidoses and yeast prions: Common threads? , 2000, Nature Medicine.
[17] L. Kiessling,et al. Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. , 2001, Biochemistry.
[18] P. Fraser,et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease , 1995, Nature Medicine.
[19] M. Hecht,et al. De novo amyloid proteins from designed combinatorial libraries. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] T. Holzman,et al. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. , 1994, Biophysical journal.
[21] Dominic M. Walsh,et al. Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.
[22] W. Surewicz,et al. The Role of Disulfide Bridge in the Folding and Stability of the Recombinant Human Prion Protein* , 2001, The Journal of Biological Chemistry.
[23] J. Vincent,et al. In Vivo Cytotoxicity of the Prion Protein Fragment 106–126* , 2000, The Journal of Biological Chemistry.
[24] B. Solomon,et al. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[25] P. Fraser,et al. Morphology and antibody recognition of synthetic β‐amyloid peptides , 1991 .
[26] H. Paulson,et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.
[27] B. Caughey,et al. Inhibition of Interactions and Interconversions of Prion Protein Isoforms by Peptide Fragments from the C-terminal Folded Domain* , 2001, The Journal of Biological Chemistry.
[28] P. Lansbury,et al. The C‐Terminus of the β Protein is Critical in Amyloidogenesis a , 1993 .
[29] S. Asano,et al. Inhibition of Amyloid Protein Aggregation and Neurotoxicity by Rifampicin , 1996, The Journal of Biological Chemistry.
[30] Regina M. Murphy,et al. Kinetics of aggregation of synthetic β-amyloid peptide , 1992 .
[31] Claudio Soto,et al. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.
[32] F E Cohen,et al. Pathologic conformations of prion proteins. , 1998, Annual review of biochemistry.
[33] G. Forloni,et al. Determination of solution conformations of PrP106-126, a neurotoxic fragment of prion protein, by 1H NMR and restrained molecular dynamics. , 1999, European journal of biochemistry.
[34] Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. , 1999 .
[35] H. Lehrach,et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] B. Caughey,et al. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] J. Collinge,et al. Structural mobility of the human prion protein probed by backbone hydrogen exchange , 1999, Nature Structural Biology.
[38] S. Hersch,et al. Huntington aggregates may not predict neuronal death in Huntington's disease. , 1999, Annals of neurology.
[39] C. Barrow,et al. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. , 1992, Journal of molecular biology.
[40] T. Benzinger,et al. Two-Dimensional Structure of β-Amyloid(10−35) Fibrils† , 2000 .
[41] R. Glockshuber,et al. Extremely rapid folding of the C-terminal domain of the prion protein without kinetic intermediates , 1999, Nature Structural Biology.
[42] J T Finch,et al. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[43] S. Hersch,et al. Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .
[44] D. Housman,et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Emmerling,et al. Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.
[46] K Wüthrich,et al. NMR solution structure of the human prion protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[47] D. Owen,et al. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. , 2000, The Biochemical journal.
[48] J. Pettegrew,et al. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. , 1998, Life sciences.
[49] J. Swatton,et al. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. , 1999, The Biochemical journal.
[50] M. Findeis,et al. Modified-peptide inhibitors of amyloid beta-peptide polymerization. , 1999, Biochemistry.
[51] C M Dobson,et al. Mutational analysis of the propensity for amyloid formation by a globular protein , 2000, The EMBO journal.
[52] Carl W. Cotman,et al. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[53] P. Lansbury,et al. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. , 1999, Biochemistry.
[54] L. Serpell,et al. Molecular structure of a fibrillar Alzheimer's A beta fragment. , 2000, Biochemistry.
[55] G P Bates,et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[56] A. Hackam,et al. Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal Cells* , 2000, The Journal of Biological Chemistry.
[57] J R Ghilardi,et al. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. , 2000, Biochemistry.
[58] P. Lansbury,et al. The C-terminus of the beta protein is critical in amyloidogenesis. , 1993, Annals of the New York Academy of Sciences.
[59] He Li,et al. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity , 2000, Nature Genetics.
[60] J. Straub,et al. Simulation study of the structure and dynamics of the Alzheimer's amyloid peptide congener in solution. , 2001, Biophysical journal.
[61] J. Kemp,et al. Controlling Polymerization of β-Amyloid and Prion-derived Peptides with Synthetic Small Molecule Ligands* , 2000, The Journal of Biological Chemistry.
[62] F E Cohen,et al. Folding of prion protein to its native alpha-helical conformation is under kinetic control. , 2001, The Journal of biological chemistry.
[63] P. Silver,et al. Polyglutamine Expansions Proteolysis, Chaperones, and the Dangers of Promiscuity , 2000, Neuron.
[64] W. Surewicz,et al. Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. , 2000, Biochemistry.
[65] T. Benzinger,et al. Two-dimensional structure of beta-amyloid(10-35) fibrils. , 2000, Biochemistry.
[66] M. Davies,et al. In-situ atomic force microscopy study of beta-amyloid fibrillization. , 2000, Journal of molecular biology.
[67] R. Cappai,et al. Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrPC , 2000, Journal of neuroscience research.
[68] Lars Terenius,et al. A Molecular Model of Alzheimer Amyloid β-Peptide Fibril Formation* , 1999, The Journal of Biological Chemistry.
[69] A. Fersht,et al. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[70] R. Leapman,et al. Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of β-sheets in Alzheimer's β-amyloid fibrils , 2000 .
[71] B. Yankner,et al. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[72] R. Snell,et al. Amyloid-like inclusions in Huntington’s disease , 2000, Neuroscience.
[73] F. Cohen,et al. Conformational propagation with prion‐like characteristics in a simple model of protein folding , 2001, Protein science : a publication of the Protein Society.
[74] James R. Burke,et al. Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening* , 2000, The Journal of Biological Chemistry.
[75] Y. Kallberg,et al. Prediction of Amyloid Fibril-forming Proteins* , 2001, The Journal of Biological Chemistry.
[76] G. Forloni,et al. Neurotoxicity of a prion protein fragment , 1993, Nature.
[77] W. B. Stine,et al. The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. , 1996, Journal of protein chemistry.
[78] J. Smith,et al. Dynamic simulation of the mouse prion protein. , 2000, Biopolymers.
[79] R A Houghten,et al. Inhibition of beta-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library. , 2000, Journal of structural biology.
[80] Fran Maher,et al. The Hydrophobic Core Sequence Modulates the Neurotoxic and Secondary Structure Properties of the Prion Peptide 106‐126 , 1999, Journal of neurochemistry.
[81] D. Kirschner,et al. Structural analysis of Alzheimer's beta(1-40) amyloid: protofilament assembly of tubular fibrils. , 1998, Biophysical journal.
[82] T. Klockgether,et al. Cell death in polyglutamine diseases , 2000, Cell and Tissue Research.
[83] L. Serpell,et al. Molecular Structure of a Fibrillar Alzheimer's Aβ Fragment† , 2000 .
[84] Peter T. Lansbury,et al. Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .
[85] A. Doig,et al. Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. , 2000, The Journal of biological chemistry.
[86] A. Doig,et al. Inhibition of Toxicity in the β-Amyloid Peptide Fragment β-(25–35) Using N-Methylated Derivatives , 2000, The Journal of Biological Chemistry.
[87] R. Leapman,et al. Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of beta-sheets in Alzheimer's beta-amyloid fibrils. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[88] B. Seilheimer,et al. The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. , 1997, Journal of structural biology.
[89] P. Fraser,et al. Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. , 1994, Journal of molecular biology.
[90] M. Chesselet,et al. Tissue-Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of Enhanced Levels of N- and C-Terminal htt Fragments in Huntington's Disease Striatum , 2001, The Journal of Neuroscience.
[91] D. Owen,et al. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. , 2000, The Biochemical journal.
[92] M. Citron,et al. Aβ-Generating Enzymes Recent Advances in β- and γ-Secretase Research , 2000, Neuron.
[93] W. B. Stine,et al. The nanometer-scale structure of amyloid-Β visualized by atomic force microscopy , 1996 .
[94] D. Kirschner,et al. Kinetic theory of fibrillogenesis of amyloid beta-protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[95] F E Cohen,et al. Prion protein peptides induce alpha-helix to beta-sheet conformational transitions. , 1995, Biochemistry.
[96] D. Housman,et al. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[97] Fred E. Cohen,et al. Folding of Prion Protein to Its Native α-Helical Conformation Is under Kinetic Control* , 2001, The Journal of Biological Chemistry.
[98] L. Kiessling,et al. A Strategy for Designing Inhibitors of β-Amyloid Toxicity* , 1996, The Journal of Biological Chemistry.
[99] S. Prusiner,et al. Structural changes in a hydrophobic domain of the prion protein induced by hydration and by ala-->Val and pro-->Leu substitutions. , 2000, Journal of molecular biology.
[100] David R. Brown. Prion Protein Peptides: Optimal Toxicity and Peptide Blockade of Toxicity , 2000, Molecular and Cellular Neuroscience.
[101] L. Kiessling,et al. Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. , 1999, Biochemistry.
[102] D C Krakauer,et al. Mapping the parameters of prion-induced neuropathology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[103] H. Minakata,et al. Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. , 2000, Biophysical journal.
[104] G Klopman,et al. Solution structure of residues 1-28 of the amyloid beta-peptide. , 1994, Biochemistry.
[105] George B. Benedek,et al. Kinetic theory of fibrillogenesis of amyloid β-protein , 1997 .
[106] D. Kirschner,et al. A beta fibrillogenesis: kinetic parameters for fibril formation from congo red binding. , 2000, Journal of structural biology.
[107] A. Takashima,et al. Three-dimensional structures of the amyloid beta peptide (25-35) in membrane-mimicking environment. , 1996, Biochemistry.